匯豐研究:升中海油(0883.HK)目標價至17.37港元 評級“買入”
匯豐環球研究發表報告表示,中海油(0883.HK)
上調今明兩年的淨產量目標至分別5.25及5.55億桶,而2022年更達到5.9億桶,同時資本開支增加至介乎850至950億元人民幣。該行指,相信中海油在持續增加產量,聚焦於成本控制及穩定的勘探計劃等因素下,對公司股價會有正面作用。
匯豐環球研究表示,上調對中海油2019至2021年每股盈利預測分別5.4%、3.7%及0.7%,各至1.36、1.39及1.65元人民幣,以反映其產量的提升,目標價相應由16.6港元升至17.37港元,維持“
買入
”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.